The instant invention provides orally administrable pharmaceutical compositions suitable for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising a therapeutically effective amount of a statin selected from dihydroxy open acid simvastatin and a pharmaceutically acceptable salt or ester thereof in a delayed-release dosage form wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.
本发明提供了可口服的药物组合物,适用于抑制
HMG-CoA 还原酶以及治疗和/或降低受
HMG-CoA 还原酶抑制影响的疾病和病症的风险,该组合物包含治疗有效量的他汀类药物,该他汀类药物选自二羟基开酸
辛伐他汀及其药学上可接受的盐或酯,采用缓释剂型,其中化合物从剂型中的实质性释放被延迟到剂型通过胃之后。